Skip to content

Effect of subanesthetic dose of esketamine on perioperative neurocognitive disorders in patients undergoing gastrointestinal surgery

Effect of subanesthetic dose of esketamine on perioperative neurocognitive disorders in patients undergoing gastrointestinal surgery: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062421
Enrollment
Unknown
Registered
2022-08-05
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative neurocognitive disorder

Interventions

Group 1:Esketamine 0.15mg/kg was given intravenously 5min before peeling
Group 2:The same amount of normal saline was given intravenously 5 minutes before peeling

Sponsors

Yixing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects: patients who underwent gastrointestinal surgery under general anesthesia in Yixing People's Hospital; 2. Age: 60 to 80 years old; 3. ASA classification I-III; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with central nervous system diseases such as Parkinson's, epilepsy, dementia, etc. before surgery; 2. Patients with severe hepatic and renal insufficiency; 3. Severe uncontrolled hypertension, glaucoma, intracranial hypertension; 4. Low education, slurred speech, unable to communicate normally; 5. Patients with severe postoperative complications and ICU admission; 6. Those who died and lost follow-up within 3 months after operation.

Design outcomes

Primary

MeasureTime frame
Cognitive function assessment;

Secondary

MeasureTime frame
TNF-a;IL-1ß;IL-6;

Countries

China

Contacts

Public ContactHan Chao

Yixing People's Hospital

staff940@yxph.com+86 13961568178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026